State Street SPDR S&P Pharmaceuticals ETF
XPH
72 hedge funds and large institutions have $105M invested in State Street SPDR S&P Pharmaceuticals ETF in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 12 closing their positions.
110,050% more call options, than puts
Call options by funds: $2.2M | Put options by funds: $2K
1.93% more ownership
Funds ownership: 45.65% → 47.58% (+1.9%)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 73 → 72 (-1)
10% less capital invested
Capital invested by funds: $117M → $105M (-$11.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$2.24M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$875K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$810K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$641K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$569K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.25M |
| 2 |
JP Morgan Chase
New York
|
-$3.61M |
| 3 |
FMP
Financial Management Professionals
Austin,
Texas
|
-$3.19M |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$2.99M |
| 5 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$2.16M |
XPH Hedge Fund Activity: Q3 2020 in Review
72 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2020, worth a combined $105M — down 9.7% from $117M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of XPH and 11 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 19 added.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $2.24M. The largest seller was Goldman Sachs, cutting an estimated $4.25M.
- 72 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2020, down from 73 in Q2 2020.
- Funds reported $105M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2020, down 9.7% quarter-over-quarter.
- 11 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2020 and 12 closed out, a net change of -1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2020 was HighTower Advisors, an estimated $2.24M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2020 was Goldman Sachs, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2020.